Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20706632 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)
Condition: HIV Infections
Intervention: Biological: HIV-1 C4-V3 Polyvalent Peptide Vaccine

Indicates status has not been verified in more than two years